hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06334185 id: pVax briefTitle: Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection. acronym: pVax overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-07-01 date: 2024-07-01 date: 2024-03-27 date: 2024-03-28 name: Azienda Ospedaliera di Lecco class: OTHER name: IRCCS Ospedale San Raffaele briefSummary: Respiratory tract infections are among the leading causes of death worldwide and many of these infections are preventable through vaccination. One of the most important bacteria from an etiological and mortality point of view regarding respiratory and systemic infections is the gram-positive Streptococcus pneumoniae. Four types of vaccines are currently available for this pathogen: three pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20) and one polysaccharide vaccine (PPSV23). In Italy, people over 65 years of age and people suffering from chronic pathologies with effects on the immune system would be advised to be vaccinated with the pneumococcal conjugate vaccine and with the polysaccharide vaccine as a second dose.
However, there are no data available in Italy on vaccination coverage in these population categories and above all the vaccination rates in patients who have a history of an episode of invasive pneumococcal infection are not known. The aim of the study is to measure how many patients are vaccinated for S. pneumoniae after hospitalization for a systemic pneumococcal infection in order to understand patients' awareness of preventing this infection after receiving a first diagnosis. conditions: Invasive Pneumococcal Infection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 320 type: ESTIMATED measure: Rate of antipneumococcal vaccination in hospitalized patients for invasive pneumococcal infection between 2015 and 2019. measure: Rate of pneumococcal serotype that caused the invasive infection in patients vaccinated prior to the infectious event sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06334172 id: H-23071221 briefTitle: The Role of Oxytocin in Regulating Blood Glucose acronym: GLOXY-1 overallStatus: RECRUITING date: 2024-01-01 date: 2026-12-31 date: 2026-12-31 date: 2024-03-27 date: 2024-04-04 name: University Hospital, Gentofte, Copenhagen class: OTHER briefSummary: Investigating the effect of oxytocin on pancreatic endocrine functions by determining insulin and glucagon secretion within physiological ranges of plasma glucose. conditions: Glucose Metabolism Disorders (Including Diabetes Mellitus) studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Randomized, double-blinded, single-arm study. Each participant goes through three experimental days in a randomized order - acting as their own controls primaryPurpose: BASIC_SCIENCE masking: DOUBLE maskingDescription: The randomized order of infusions is blinded to both participant and investigator whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 20 type: ESTIMATED name: Oxytocin name: Placebo measure: Insulin secretion - c-peptide measure: Glucose measure: Insulin measure: Glucagon measure: GIP measure: GLP-1 measure: Lipids measure: Cross-linked C-telopeptide of type I collagen( CTX) measure: Procollagen type I N-terminal propeptide (P1NP) sex: MALE minimumAge: 20 Years maximumAge: 50 Years stdAges: ADULT facility: Center for Clinical Metabolic Research, Gentofte Hospital status: RECRUITING city: Hellerup state: Capital Region zip: 2900 country: Denmark name: Filip K Knop, MD, PhD role: CONTACT phone: 004538674266 email: filip.krag.knop.01@regionh.dk lat: 55.73204 lon: 12.57093 hasResults: False
nctId: NCT06334159 id: PER-ECL-2019-08 briefTitle: Guided Bone Regeneration Using Fixed vs Non-Fixed Resorbable Collagen Membranes overallStatus: RECRUITING date: 2020-11-05 date: 2025-07-20 date: 2027-07-20 date: 2024-03-27 date: 2024-03-27 name: Universitat Internacional de Catalunya class: OTHER briefSummary: The aim of this clinical trial is to compare the horizontal bone gain when grafting a bone substitute with non fixed resorbable collagen membranes (control group), versus fixed resorbable collagen membranes (test group) in resorbed ridges requiring Guided Bone Regeneration (GBR) to facilitate implant placement at 6 months. conditions: Bone Resorption studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: non fixed resorbable collagen membranes (control group), versus fixed resorbable collagen membranes (test group) primaryPurpose: TREATMENT masking: NONE count: 26 type: ESTIMATED name: Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane name: Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane measure: Horizontal Bone Gain measure: Bone Width Gain measure: Horizontal Dimensional Stability measure: Post-surgical complications measure: Patient's satisfaction measure: Histologic examination of the augmented bone at 6 months sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Georgios Markantonatos status: RECRUITING city: Barcelona state: Sant Cugat Del Vallès zip: 08195 country: Spain name: Georgios Markantonatos, DDS role: CONTACT phone: +34666022568 email: giorgosmark@uic.es name: Cristina Vallès, DDS, MS, PhD role: PRINCIPAL_INVESTIGATOR lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06334146 id: UNLV-2023-62 briefTitle: Tap Dance for Adults With Lower Limb Amputation overallStatus: RECRUITING date: 2024-03-04 date: 2025-05 date: 2025-05 date: 2024-03-27 date: 2024-03-27 name: University of Nevada, Las Vegas class: OTHER briefSummary: The goal of this study is to determine whether it is possible for people with lower limb amputation (LLA) to perform adapted tap dance, whether an adapted tap dance program would be enjoyable, and whether it may improve balance and balance confidence.
There is a lack of research investigating therapeutic interventions for people with lower limb amputation (LLA). Tap dance encourages balance and novel movements of the limbs, while providing auditory feedback from the feet that provide information about the foot's contact with the ground, which may help prosthesis users gain a better ability to understand where their prosthetic foot is in space. As with most forms of dance, tap is usually taught and practiced in a group setting, which encourages community involvement. It has been shown to be safer than many forms of dance due to low impact forces. It also, as a genre, can incorporate canes, chairs and partner work, providing the ability to modify steps/moves when required so that they remain practical, achievable and safe for people with mobility limitations, while still enabling participation. It therefore may be an accessible dance medium to help improve balance, balance confidence, and build community for people with LLA.
* complete questionnaires before, during and after the program. The total time for participation is approximately 8-10 weeks. conditions: Amputation; Traumatic, Leg, Lower studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 6 type: ESTIMATED name: Tap dance program measure: Session Adherence measure: Physical Activities Enjoyment Scale (PACES) measure: Change in Timed Up-and-Go test score measure: Change in Four Square Step Test score measure: Change in Berg Balance Scale score measure: Change in Activities-Specific Balance Confidence Scale score measure: Physical Activities Enjoyment Scale (PACES) score - Mid program measure: Change in Trinity Amputation and Prosthesis Experience Scale (TAPES) functional activity restriction subscale score measure: Change in Trinity Amputation and Prosthesis Experience Scale (TAPES) social activity restriction subscale score measure: Change in Trinity Amputation and Prosthesis Experience Scale (TAPES) athletic activity restriction score measure: Use of assistive devices per session measure: Session completion per session sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Nevada Las Vegas status: RECRUITING city: Las Vegas state: Nevada zip: 89154 country: United States name: Jenny Kent, PhD role: CONTACT phone: 702-895-5949 email: jenny.kent@unlv.edu lat: 36.17497 lon: -115.13722 hasResults: False
nctId: NCT06334133 id: TTP399-302 briefTitle: Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes acronym: CATT1 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-06 date: 2026-03 date: 2024-03-27 date: 2024-04-01 name: vTv Therapeutics class: INDUSTRY briefSummary: This is a Phase 3 trial of cadisegliatin in participants with Type 1 Diabetes Mellitus. conditions: Diabetes Mellitus, Type 1 studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 150 type: ESTIMATED name: Cadisegliatin 800 mg QD name: Cadisegliatin 800 mg BID name: Placebo measure: Change in incidence of Level 2 or Level 3 hypoglycemia measure: To assess the change in HbA1c measure: To assess the effects of treatment on CGM-based metrics for glycemic control measure: To assess the effects of treatment on the incidence of diabetic ketoacidosis measure: To assess the effects of treatment on insulin dosing measure: To assess the effects of treatment on body weight measure: To assess the incidence of adverse events measure: Change in incidence of Level 2 or Level 3 hypoglycemia measure: To assess the change in HbA1c measure: To assess the effects of treatment on CGM-based metrics for glycemic control measure: To assess the incidence of adverse events measure: To assess the effects of treatment on the incidence of diabetic ketoacidosis measure: To assess the effects of treatment on insulin dosing measure: To assess the effects of treatment on body weight measure: High sensitivity C-reactive protein measure: N-terminal pro brain [or B-type] natriuretic peptide measure: Urinary albumin excretion ratio measure: Estimated glomerular filtration rate measure: Gold hypoglycemia awareness score measure: Item 7 of Clarke hypoglycemia awareness scale measure: Snyder's 1-item quality of sleep questionnaire measure: World Health Organization-5 Well-Being Index measure: 8-item Diabetes Distress Scale (participant and partner or family member) measure: Hypoglycemia Confidence Scale for participant and partner or family member measure: 11-item/Short Form Hypoglycemia Fear Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06334120 id: 20654 briefTitle: An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2025-09-30 date: 2026-03-31 date: 2024-03-27 date: 2024-03-27 name: Bayer class: INDUSTRY briefSummary: This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels.
Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events. conditions: Non-metastatic Castration-resistant Prostate Cancer conditions: Metastatic Hormone-sensitive Prostate Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 600 type: ESTIMATED name: Darolutamide (Nubeqa, BAY1841788) measure: Number, severity of adverse events (including SAEs) measure: Number, severity of adverse drug reactions (including SADRs) measure: The outcome of (serious) adverse events measure: The outcome of (serious) adverse drug reactions measure: Metastasis-free survival (MFS) measure: Time to symptomatic skeletal event (SSE) measure: Time to prostate-specific antigen (PSA) progression measure: Number of patients with metastasis of castration-resistant prostate cancer (mCRPC) measure: Overall survival measure: Duration of Darolutamide treatment measure: Reasons for ending Darolutamide measure: Dosage and dose modification of Darolutamide sex: MALE minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Multiple locations city: Multiple Locations country: Korea, Republic of hasResults: False
nctId: NCT06334107 id: 24AIREA1191995 briefTitle: Mitochondrial DNA Signatures of Poor Aerobic Exercise Trainability in Young Adults Born Preterm overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-01 date: 2025-12-31 date: 2024-03-27 date: 2024-03-27 name: Texas Tech University class: OTHER briefSummary: Young adults born very preterm (32 weeks gestation or earlier) do not respond well to aerobic exercise training, meeting the recommendations set by the Physical Activity Guidelines for Americans, where they do not increase their fitness level (or cardiorespiratory fitness). Thus, they do not receive the health benefits of exercise. Achieving physical fitness through aerobic exercise training is the most cost-effective method for preventing and treating many diseases. Young adults born very preterm also have a higher risk of these conditions. Thus, their inability to respond to increase their fitness is a major problem.
One likely explanation for poor exercise trainability and increased heart disease risk in young adults born very preterm is the effect of the early birth on the major energy producers in all our cells: Mitochondria. During late-stage gestation, mitochondria change from relying on sugar as a major fuel source to fat. Unfortunately, individuals born very preterm miss this transition in fuel source reliance, which causes significant stress and damage to mitochondria. Mitochondria are critical for post-natal organ development; thus, it is thought that preterm birth-induced mitochondrial dysfunction is the underlying cause of poor trainability and high disease risk in young adults born very preterm. Indeed, mitochondrial dysfunction is evident in these individuals.
The investigators expect this work will show mitochondrial DNA changes linked to mitochondrial dysfunction and poor trainability, which can be used for future targets to improve health. This work supports AHA mission by helping to identify a marker in individuals born very preterm linked to their higher heart disease risk and death early in life. conditions: Preterm Birth studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 45 type: ESTIMATED name: Exercise measure: Mitochondrial DNA heteroplasmy measure: Mitochondrial DNA sequence variants measure: Change in maximal aerobic capacity measure: Change in mitochondrial oxidative capacity in peripheral blood mononuclear cells measure: Daily sleep habits sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT hasResults: False
nctId: NCT06334094 id: IRB-23-486 id: IM047-1054 type: OTHER_GRANT domain: Bristol Myers Squibb briefTitle: Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2028-03-31 date: 2028-05-31 date: 2024-03-27 date: 2024-03-27 name: The University of Texas at Dallas class: OTHER name: Texas Institute for Neurological Disorders briefSummary: The primary objective of this study is to investigate the cognitive benefits of ozanimod in individuals with Multiple Sclerosis (MS). The study aims to understand the neural basis of cognitive improvement in Relapsing-Remitting MS patients under ozanimod treatment using neuroimaging and behavioral techniques to characterize the brain and behavioral changes due to ozanimod treatment. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Ozanimod measure: Change in Processing Speed/Symbol-Digit Modality Test (SDMT) Performance measure: Change in Volumetric Blood-Oxygen-Level-Dependent (BOLD) signal as Measured by Dual Echo Functional Magnetic Resonance Imaging (fMRI) measure: Change in Cerebral Blood Flow (CBF) as Measured by Dual Echo Functional Magnetic Resonance Imaging (fMRI) measure: Change in Cerebral Metabolic Rate of Oxygen (CMRO2) as Measured by Dual Echo Functional Magnetic Resonance Imaging (fMRI) measure: Change in Whole Brain Volume as Measured By Structural Magnetic Resonance Imaging measure: Differences in Diffusion parameters of ozanimod-responders to non-responders as Measured By a Diffusion Kurtosis Resonance Imaging (DKI) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center for Brain Health city: Dallas state: Texas zip: 75228 country: United States name: Jessica Ma, BS role: CONTACT phone: 972-883-3414 email: jxm180043@utdallas.edu name: Ashley M Campos, MA role: CONTACT email: amc230006@utdallas.edu name: Bart Rypma, PhD role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06334081 id: A02040230S briefTitle: Different Surgical Drilling Protocols in Posterior Maxilla overallStatus: ACTIVE_NOT_RECRUITING date: 2023-06-29 date: 2023-12-30 date: 2024-06-30 date: 2024-03-27 date: 2024-03-27 name: Mansoura University class: OTHER briefSummary: Sixteen dental implants inserted in sixteen patients who were selected from the outpatient clinic of the Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Mansoura University, for the rehabilitation of missed single maxillary posterior tooth by an immediately loaded dental implants conditions: Missing Teeth studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 16 type: ACTUAL name: undersized drilling technique name: single drilling technique measure: bone density measurement measure: marginal bone loss sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Heba Elsheikh city: Mansoura country: Egypt lat: 31.03637 lon: 31.38069 hasResults: False
nctId: NCT06334068 id: MS.24.03.2725 briefTitle: SHOrt-term Glycemic Control for Reducing Post-SURGical Complications acronym: Surg-ShoGR overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-09 date: 2024-10 date: 2024-03-27 date: 2024-03-27 name: Mansoura University class: OTHER briefSummary: Perioperative dysglycemia-hyperglycemia, hypoglycemia, and glycemic variability-is associated with an increased risk for adverse outcomes. Several studies have reported the association between elevated preoperative HbA1c and postoperative complications.
2. Standard-of-care group: Patients will be admitted the day before surgery with the usual patient treatment. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: The outcome assessors, who will call patients or relatives 30 days after surgery, will be masked for the allocated group. whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Short-term glycemic control group name: Standard-of-care group measure: Number of days at home after surgery (DAH-30). measure: Loss of follow-up after surgery measure: Loss of follow up after the clinic preoperative assessment measure: 30-day mortality measure: Length of hospital stay measure: incidence of postoperative complications measure: Quality of Recovery15 (QoR-15) measure: Time to resumption of normal diabetes therapy measure: Incidence of diabetic ketoacidosis or hypoglycemia measure: Incidence of use of intravenous insulin infusion therapy measure: Duration of use of intravenous insulin infusion therapy measure: Change in diabetic management at 30 days sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Moataz Maher Emara city: Mansoura state: Aldakahlia zip: 35516 country: Egypt name: Moataz M Emara, MD, EDAIC role: CONTACT phone: 01064048848 email: mm.emara@mans.edu.eg lat: 31.03637 lon: 31.38069 hasResults: False
nctId: NCT06334042 id: GO 23/488 briefTitle: Examination of the Effects of Chromium Levels on Glucose Metabolism, Lipid Metabolism, Morbidity and Mortality Rates in Patients Followed in Intensive Care Unit overallStatus: RECRUITING date: 2024-02-01 date: 2024-08-01 date: 2024-09-01 date: 2024-03-27 date: 2024-03-27 name: Oguzhan Kahveci class: OTHER briefSummary: The goal of this observational study is to learn about the effects of chromium serum levels on glucose metabolism, lipid metabolism, morbidity and mortality rates in critically ill intensive care patients. The investigators' goal is to provide a different perspective on solving the common problems of hyperglycemia and dyslipidemia encountered in intensive care patients, aiming to reduce morbidity and mortality rates.
Participants will give a single blood sample (into trace element serum tube) on the day of admission to the intensive care unit, along with routine blood tests, and samples will be taken once a week during their stay in the intensive care unit. conditions: Chromium Deficiency conditions: Diabetes Mellitus conditions: Hyperlipidemias conditions: Hypercholesterolemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 350 type: ESTIMATED name: Serum Chromium Level measure: Serum Chromium Level measure: HbA1c measure: Blood Glucose measure: Lipid Profile sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hacettepe University status: RECRUITING city: Ankara zip: 06230 country: Turkey name: Oguzhan Kahveci, MD role: CONTACT phone: +903123051207 email: oguzhan.kahveci@hacettepe.edu.tr lat: 39.91987 lon: 32.85427 hasResults: False